Company news

Delcath Systems, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

December 29, 2024

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

December 1, 2024

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

November 7, 2024

Delcath Systems to Host Third Quarter 2024 Earnings Call

October 24, 2024

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

October 16, 2024

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

September 15, 2024

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

August 27, 2024

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

August 26, 2024

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

August 25, 2024

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

August 19, 2024

Delcath Systems Reports Second Quarter 2024 Results and Business Highlights

August 4, 2024

Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™

August 4, 2024

Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath’s Board of Directors

May 27, 2024

Delcath Systems Reports First Quarter 2024 Results and Business Highlights

May 13, 2024

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2024

Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

March 25, 2024

Delcath Systems Closes $7 Million Private Placement

March 19, 2024

Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call

March 18, 2024

Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

March 17, 2024

Delcath Systems Announces $7 Million Private Placement

March 14, 2024

Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

February 21, 2024

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

January 30, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™

January 15, 2024

Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 14, 2023

Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update

November 12, 2023

Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers

October 15, 2023

Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™

August 31, 2023

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

August 13, 2023

Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update

August 8, 2023

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

June 19, 2023

Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance

June 6, 2023

Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results

May 11, 2023

Delcath Systems Announces Resumption of Interest-Only Period for Company's Debt Facility

April 2, 2023

Delcath Systems Announces Closing of Private Placement of up to $85 Million

March 28, 2023

Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

March 26, 2023

Delcath Systems, Inc. Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023

March 26, 2023

Delcath Systems Announces up to $85 Million Financing

March 26, 2023

Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch

February 15, 2023

Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit

February 13, 2023

Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology

January 16, 2023

Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4)

December 15, 2022

Delcath Systems Closes Private Placement of $6.2 Million

December 12, 2022

Delcath Systems Announces Private Placement of $6.2 Million

December 7, 2022

Delcath Systems Reports Third Quarter 2022 Results and Provides Business Update

November 7, 2022

Delcath Systems Reports Second Quarter 2022 Results and Provides Business Update

August 7, 2022

Delcath Systems Closes Private Placement of $5.0 Million

July 19, 2022

Delcath Systems Announces Private Placement of $5.0 Million

July 17, 2022

Delcath Systems Reports First Quarter 2022 Results and Provides Business Update

May 9, 2022

Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting

May 8, 2022

Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update

March 24, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 59 decks. Every deck is listed under its year.